ARROWHEAD PHARMACEUTICALS, INC. Proceeds from Contributed Capital
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Proceeds from Contributed Capital of $0 for the 12-month period ending 2024-09-30, per its 10-K filed 2024-11-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromContributedCapital · last filed 2024-11-26
- ARROWHEAD PHARMACEUTICALS, INC. proceeds from contributed capital for the quarter ending 2023-09-30 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. proceeds from contributed capital for the quarter ending 2023-06-30 was -$250.00M, a 516.67% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. proceeds from contributed capital for the quarter ending 2023-03-31 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. proceeds from contributed capital for the quarter ending 2022-12-31 was $250.00M.
- ARROWHEAD PHARMACEUTICALS, INC. proceeds from contributed capital for fiscal 2024 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. proceeds from contributed capital for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- ARROWHEAD PHARMACEUTICALS, INC. proceeds from contributed capital for fiscal 2022 was $60.00M.
- ARROWHEAD PHARMACEUTICALS, INC. proceeds from contributed capital for fiscal 2021 was $0.00.
| Period end | Proceeds from Contributed Capital 3 month | Proceeds from Contributed Capital 6 month | Proceeds from Contributed Capital 9 month | Proceeds from Contributed Capital 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 10-K · filed 2024-11-26 | |||
| 2023-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26 | -$250.00M derived: sum of 2 quarters · filed 2024-11-26 | -$250.00M derived: sum of 3 quarters · filed 2024-11-26 | $0.00 10-K · filed 2024-11-26 |
| 2023-06-30 | -$250.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-07 | -$250.00M derived: sum of 2 quarters · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | $0.00 derived: sum of 4 quarters · filed 2024-11-26 |
| 2023-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-02 | $250.00M 10-Q · filed 2023-05-02 | $250.00M derived: sum of 3 quarters · filed 2024-11-26 | $310.00M derived: sum of 4 quarters · filed 2024-11-26 |
| 2022-12-31 | $250.00M 10-Q · filed 2023-02-06 | $250.00M derived: sum of 2 quarters · filed 2024-11-26 | $310.00M derived: sum of 3 quarters · filed 2024-11-26 | $310.00M derived: sum of 4 quarters · filed 2024-11-26 |
| 2022-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26 | $60.00M derived: sum of 2 quarters · filed 2024-11-26 | $60.00M derived: sum of 3 quarters · filed 2024-11-26 | $60.00M 10-K · filed 2024-11-26 |
| 2022-06-30 | $60.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-07 | $60.00M derived: sum of 2 quarters · filed 2023-08-07 | $60.00M 10-Q · filed 2023-08-07 | $60.00M derived: sum of 4 quarters · filed 2023-11-29 |
| 2022-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-02 | $0.00 10-Q · filed 2023-05-02 | $0.00 derived: sum of 3 quarters · filed 2023-11-29 | |
| 2021-12-31 | $0.00 10-Q · filed 2023-02-06 | $0.00 derived: sum of 2 quarters · filed 2023-11-29 | ||
| 2021-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-29 | $0.00 10-K · filed 2023-11-29 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 | |||
| 2020-09-30 | $0.00 10-K · filed 2022-11-28 | |||
| 2012-12-31 | $1.00M 10-Q · filed 2013-02-13 | |||
| 2012-09-30 | $1.00M 10-Q · filed 2013-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |